Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186849 · ClinicalTrials.gov registry record · Phase 2
Therapy for Children With Advanced Stage High Risk Neuroblastoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00186849 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 30 participants.
The verdict
NCT00186849, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Interventions
- PROCEDURE Peripheral Blood Stem Cell Transplant
- DRUG Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-10 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186849
The ClinicalTrials.gov registry entry for NCT00186849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Peripheral Blood Stem Cell Transplant is the first listed.
NCT00186849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186849 about?
NCT00186849 is a clinical study titled "Therapy for Children With Advanced Stage High Risk Neuroblastoma". This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront win...
What is the current status of trial NCT00186849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1997-10. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00186849?
The interventions under investigation include: Peripheral Blood Stem Cell Transplant (PROCEDURE), Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00186849?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.